The Conversation (0)
Leap Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Result
Feb. 23, 2018 09:47AM PST
Biotech InvestingLeap Therapeutics (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2017. Leap additionally announced that its Annual Meeting of Stockholders will be held on Thursday, May 3, 2018, at 11:00 a.m., Eastern Time, at the offices of Morgan, Lewis & Bockius …
Leap Therapeutics (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2017. Leap additionally announced that its Annual Meeting of Stockholders will be held on Thursday, May 3, 2018, at 11:00 a.m., Eastern Time, at the offices of Morgan, Lewis & Bockius LLP, One Federal Street, Boston, Massachusetts 02110.
As quoted in the press release:
“We had a very successful 2017 at Leap, our first year as a public company. We have advanced clinical development of both of our innovative cancer programs to explore novel combinations with immunotherapies and chemotherapies and have laid the foundation for a data-rich 2018,” said Christopher K. Mirabelli, Ph.D., Chief Executive Officer of Leap. “We additionally strengthened our balance sheet to continue to grow the company and further advance our pipeline.”